Fax: (011) 39-0516364037
A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma
Version of Record online: 11 JAN 2008
Copyright © 2008 American Cancer Society
Volume 112, Issue 4, pages 856–862, 15 February 2008
How to Cite
Zinzani, P. L., Tani, M., Fanti, S., Stefoni, V., Musuraca, G., Vitolo, U., Perrotti, A., Fina, M., Derenzini, E. and Baccarani, M. (2008), A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma. Cancer, 112: 856–862. doi: 10.1002/cncr.23236
- Issue online: 1 FEB 2008
- Version of Record online: 11 JAN 2008
- Manuscript Accepted: 10 SEP 2007
- Manuscript Revised: 31 AUG 2007
- Manuscript Received: 27 JUN 2007
- Bologna Italian Leukemia, Lymphoma, Multiple Myeloma Association
- 7Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. J Clin Oncol. 1992; 109: 790–794., , , et al.
- 23The addition of rituximab of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of German Low-Grade Lymphoma Study Group. Blood. 2004; 104: 3064–3071., , , et al.
- 24Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006; 108: 4003–4008., , , et al.
- 25European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol. 2000; 18: 317–324., , , et al.
- 30Randomized controlled trial of Yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2000; 20: 2453–2463., , , et al.
- 36Statisticaltables for design of clinical trials. Oxford, United Kingdom: Blackwell; 1987., .